Teicoplanin

Drug Profile

Teicoplanin

Alternative Names: MDL 507; Targocid; Teichomycin

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Class Antibacterials; Glycopeptides; Peptide antibiotics
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bacterial infections; Gram-positive infections

Most Recent Events

  • 11 Sep 2005 Vicuron Pharmaceuticals has been acquired and merged into Pfizer
  • 11 Apr 2005 Yamanouchi has merged with Fujisawa to form Astellas Pharma
  • 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top